Jane H. Hollingsworth

Jane Hollingsworth is the founding Managing Partner of Militia Hill Ventures (MHV), an organization that creates, builds, and invests in life sciences companies. While at MHV, she co-founded and currently serves as Executive Chair of Eliksa Therapeutics, a regenerative medicine company, co-founded and served as Executive Chair of Spirovant Sciences, a gene therapy company sold to Sumitomo Dainippon Pharma, and served as Executive Chair and CEO of Immunome Inc. (NASDAQ: IMNM), a cancer immunotherapy company. Prior to MHV, Jane was co-founder and CEO of NuPathe Inc. (NASDAQ: PATH), a neuroscience-focused biopharmaceutical company (sold to Teva). She also co-founded and served as EVP of Auxilium Pharmaceuticals (NASDAQ: AUXL), a urology and rare disease-focused biopharmaceutical company (sold to Endo Pharmaceuticals). Prior to founding and leading multiple biopharmaceutical companies, Ms. Hollingsworth was VP, Secretary & General Counsel of IBAH, Inc. (NASDAQ: IBAH), a multinational clinical research organization. Before joining IBAH, she practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads, and served as a law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware. As a leader in the entrepreneurial and life sciences communities, Ms. Hollingsworth also serves on various industry and community boards, including Diffusion Pharmaceuticals, Afimmune Ltd., DS BioPharma, RiboNova, the University City Science Center, the Kimmel Center for the Performing Arts, and Breastcancer.Org. She received a BA from Gettysburg College and a JD from the Villanova University School of Law.